Blueprint Medicines Corp (NASDAQ:BPMC) has a beta value of 181.14% and has seen 2.66 shares traded in the last trading session. The company, currently valued at $8.29B, closed the last trade at $128.12 per share which meant it lost -$2.48 on the day or 128.20% during that session. The BPMC stock price is -0.17% off its 52-week high price of $128.34 and 42.99% above the 52-week low of $73.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.45 million shares traded. The 3-month trading volume is 1.70 shares.
The consensus among analysts is that Blueprint Medicines Corp (BPMC) is Buy stock at the moment, with a recommendation rating of 75.62. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 10 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.53.
Blueprint Medicines Corp (NASDAQ:BPMC) trade information
Sporting 128.20% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BPMC stock price touched $128.12 or saw a rise of 0.16%. Year-to-date, Blueprint Medicines Corp shares have moved 23.42%, while the 5-day performance has seen it change -0.01%. Over the past 30 days, the shares of Blueprint Medicines Corp (NASDAQ:BPMC) have changed 24.47%. Short interest in the company has seen 6.08 million shares shorted with days to cover at 7.19.
Wall Street analysts have a consensus price target for the stock at $141, which means that the shares’ value could jump 9.13% from current levels. The projected low price target is $132.0 while the price target rests at a high of $150.0. In that case, then, we find that the current price level is -17.08% off the targeted high while a plunge would see the stock gain -3.03% from current levels.
Blueprint Medicines Corp (BPMC) estimates and forecasts
The company’s shares have gained 34.40% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 41.62%.
17 analysts offering their estimates for the company have set an average revenue estimate of 171.34M for the current quarter. 17 have an estimated revenue figure of 191.05M for the next ending quarter. Year-ago sales stood 138.16M and 128.18M respectively for this quarter and the next, and analysts expect sales will grow by 24.01% for the current quarter and 41.62% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 54.06% 31.87% over the past 5 years.
BPMC Dividends
Blueprint Medicines Corp is expected to release its next earnings report on 2025-May-01 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 0.33 at a share yield of 0.26%. The company’s dividend yield has gone up over the past 12 months.
Blueprint Medicines Corp (NASDAQ:BPMC)’s Major holders
Insiders own 0.86% of the company shares, while shares held by institutions stand at 109.41% with a share float percentage of 110.36%. Investors are also buoyed by the number of investors in a company, with Blueprint Medicines Corp having a total of 489.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 6.65 million shares worth more than $716.45 million. As of 2024-06-30, BLACKROCK INC. held 10.5758% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.54 million shares as of 2024-06-30. The firm’s total holdings are worth over $704.72 million and represent 10.4026% of shares outstanding.
